Clinical Trial Update: Study of Safety and Immunogenicity of BVRS-GamVac-Combi [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety and immunogenicity of BVRS-GamVac-Combi for MERS is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle East Respiratory Syndrome

Drugs mentioned

• BVRS-GamVac-Combi

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: MERS (Middle East Respiratory Syndrome), MERS | Phase 1, Phase 2 | Status: UNKNOWN